Artificial Intelligence and Pathomics: Prostate Cancer.

Journal: The Urologic clinics of North America
Published Date:

Abstract

Artificial intelligence (AI) has the potential to transform pathologic diagnosis and cancer patient management as a predictive and prognostic biomarker. AI-based systems can be used to examine digitally scanned histopathology slides and differentiate benign from malignant cells and low from high grade. Deep learning models can analyze patient data from individual or multimodal combinations and identify patterns to be used to predict the response to different therapeutic options, the risk of recurrence or progression, and the prognosis of the newly diagnosed patient. AI-based models will improve treatment planning for patients with prostate cancer and improve the efficiency and cost-effectiveness of the pathology laboratory.

Authors

  • Puria Azadi Moghadam
    Department of Electrical and Computer Engineering, University of British Columbia, 2332 Main Mall, Vancouver, British Columbia V6T 1Z4, Canada.
  • Ali Bashashati
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • S Larry Goldenberg
    University of British Columbia, Vancouver, BC, Canada.